Concepedia

Hyo-Yeon Kim

HK

Statistics

Publications

7

Citations

439

H-Index

7

Active since

2009

Affiliations

Sungkyunkwan University(Current)

Samsung Medical Center

The Catholic University of Korea Seoul St. Mary's Hospital

Yonsei University

National Cancer Center

Hyo-Yeon Kim is an author at Sungkyunkwan University specializing in pharmacology, medicine, and hepatotoxicity mechanisms.

Publications per year

2009–2016

7

Publications

7

Ferulic acid protects against carbon tetrachloride-induced liver injury in mice

Hyo-Yeon Kim, Juhyun Park, Kwan-Hoo Lee et al. · Toxicology · 2011 · 171 citations

Veterinary Medicine, Pharmacology, Toxicology +12

Clinical activity and safety of HM61713, an EGFR-mutant selective inhibitor, in advanced non-small cell lung cancer (NSCLC) patients (pts) with EGFR mutations who had received EGFR tyrosine kinase inhibitors (TKIs).

Dong‐Wan Kim, Jin Hyoung Kang, Keunchil Park et al. · Journal of Clinical Oncology · 2014 · 70 citations

Medicine, Oncology, Pharmacology +16

Ferulic acid attenuates ischemia/reperfusion-induced hepatocyte apoptosis via inhibition of JNK activation

Hyo-Yeon Kim, Sun‐Mee Lee · European Journal of Pharmaceutical Sciences · 2012 · 60 citations

Life Sciences, Cell Biology, Pharmacology +14

Immunomodulating effects of Korean mistletoe lectin in vitro and in vivo

Chanho Lee, Joon-Ki Kim, Hyo-Yeon Kim et al. · International Immunopharmacology · 2009 · 48 citations

Life Sciences, Immunology, Immunopathology +11

BI 1482694 (HM61713), an EGFR mutant-specific inhibitor, in T790M+ NSCLC: Efficacy and safety at the RP2D.

Keunchil Park, Jong-Seok Lee, Ki Hyeong Lee et al. · Journal of Clinical Oncology · 2016 · 42 citations

Medicine, Oncology, Pharmacology +15

1–5 of 7